Insomnia and anxiety
Conditions
Interventions
Group 1 :Jieyu pills plus escitalopram oxalate tablets
Group 2:Escitalopram oxalate tablets alone
Sponsors
The First Affiliated Hospital of Henan University of Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: (1) Insomnia and anxiety after COVID-19 infection. (2) Male and female aged 18-65 years. (3) The symptoms of the patient appeared after COVID-19 infection including sleep mood disorders depression anxiety insomnia and fatigue as the main clinical symptoms. (4) HAMA score > 14 indicating mild to moderate anxiety. (5) Consistent with the diagnosis of TCM liver depression and qi stagnation. (6) Patients were informed signed the informed consent and could be followed up with good compliance. (7) No other other anti-anxiety and depression drugs in the past 4 weeks.
Exclusion criteria
Exclusion criteria: (1) Patient with serious heart brain respiratory digestive endocrine blood liver and kidney diseases; (2) Patients with a history of mental illness disturbance of consciousness cognitive impairment or other reasons were unable to cooperate with the researcher; (2) Pregnant or lactating women; (3) Long-term alcoholism and drug dependence; (4) Ppatients with allergic constitution or allergic to drug components.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hamilton Anxiety Scale (HAMA); | — |
Secondary
| Measure | Time frame |
|---|---|
| Insomnia Severity Index (ISI);Hamilton Depression Scale (HAMD);Quantitative criteria for TCM syndrome grading;Quality of life Scale;Health Questionnaire-15 Somatic Symptom Cluster Scale (PHQ-15);Polysomnography was performed; | — |
Countries
China
Contacts
Public ContactXu Liran
The First Affiliated Hospital of Henan University of Chinese Medicine
Outcome results
None listed